S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Launched by SWOG CANCER RESEARCH NETWORK · Mar 16, 2004
Trial Information
Current as of June 18, 2025
Terminated
Keywords
ClinConnect Summary
OBJECTIVES: I. Compare the progression-free and overall survival of patients with relapsed or refractory, CD20 expressing, aggressive, B-cell non-Hodgkin's lymphoma treated with ifosfamide, carboplatin, and etoposide with or without rituximab. II. Compare the unconfirmed response rate of patients treated with these regimens. III. Determine the toxicity of ifosfamide, carboplatin, and etoposide with rituximab in these patients.
OUTLINE: This is a randomized study. Patients are stratified according to histology (large B-cell vs other) and risk group (low/low-intermediate vs high-intermediate...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Histologically proven aggressive B-cell non-Hodgkin's lymphoma that has failed prior combination chemotherapy with an anthracycline-containing regimen Eligible histologies: Diffuse large cell Small non-cleaved cell/Burkitt's lymphoma No lymphoblastic or mantle cell lymphoma First relapse or primary refractory disease Ineligible for or refused treatment with salvage chemotherapy followed by high-dose therapy and autologous stem cell rescue Documented CD20 antigen expression Measurable disease No clinical evidence of CNS involvement by lymphoma
- • PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Zubrod 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min Other: HIV negative Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- • PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior rituximab Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: Recovered from toxic effects of all prior therapy No other concurrent therapy unless disease progression occurs
About Swog Cancer Research Network
The SWOG Cancer Research Network is a leading cancer clinical trial organization dedicated to improving cancer treatment and outcomes through innovative research. Comprising a collaborative network of academic institutions, community hospitals, and cancer centers, SWOG conducts rigorous clinical trials that advance the understanding of cancer biology, prevention, and therapy. With a strong emphasis on inclusivity and diversity, SWOG aims to ensure that clinical research reflects the populations affected by cancer, ultimately striving to enhance patient care and quality of life. Through its commitment to scientific excellence and collaboration, SWOG plays a pivotal role in shaping the future of oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oklahoma City, Oklahoma, United States
Tucson, Arizona, United States
Ann Arbor, Michigan, United States
Los Angeles, California, United States
Orange, California, United States
Lexington, Kentucky, United States
Jackson, Mississippi, United States
Cincinnati, Ohio, United States
Spartanburg, South Carolina, United States
Dallas, Texas, United States
Sacramento, California, United States
Wichita, Kansas, United States
San Antonio, Texas, United States
Phoenix, Arizona, United States
Atlanta, Georgia, United States
Kansas City, Missouri, United States
Maywood, Illinois, United States
Denver, Colorado, United States
Detroit, Michigan, United States
Seattle, Washington, United States
Long Beach, California, United States
Martinez, California, United States
Oakland, California, United States
Santa Rosa, California, United States
Travis Air Force Base, California, United States
Lexington, Kentucky, United States
New Orleans, Louisiana, United States
Jamaica Plain, Massachusetts, United States
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
Saint Louis, Missouri, United States
Springfield, Missouri, United States
Billings, Montana, United States
Columbus, Ohio, United States
Dayton, Ohio, United States
Kettering, Ohio, United States
Portland, Oregon, United States
Greenville, South Carolina, United States
Seattle, Washington, United States
Albuquerque, New Mexico, United States
Temple, Texas, United States
Honolulu, Hawaii, United States
Cleveland, Ohio, United States
Mobile, Alabama, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Little Rock, Arkansas, United States
Duarte, California, United States
Los Angeles, California, United States
Denver, Colorado, United States
Fort Gordon, Georgia, United States
Decatur, Illinois, United States
Hines, Illinois, United States
Wichita, Kansas, United States
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Shreveport, Louisiana, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Southfield, Michigan, United States
Biloxi, Mississippi, United States
Jackson, Mississippi, United States
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Cincinnati, Ohio, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
San Antonio, Texas, United States
Temple, Texas, United States
Salt Lake City, Utah, United States
Seattle, Washington, United States
Seattle, Washington, United States
Tacoma, Washington, United States
Phoenix, Arizona, United States
Kansas City, Kansas, United States
Grand Rapids, Michigan, United States
Keesler Afb, Mississippi, United States
Fort Sam Houston, Texas, United States
Lubbock, Texas, United States
Portland, Oregon, United States
Galveston, Texas, United States
Dallas, Texas, United States
Salt Lake City, Utah, United States
Patients applied
Trial Officials
David G. Maloney, MD, PhD
Study Chair
Fred Hutchinson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials